Myeloma: Thalidomide as salvage therapy for VAD-refractory multiple myeloma priorto autologous PBSCT

Bone Marrow Transplantation

Volumn 29, Issue 7, 2002, Pages 577-580

  Ahmad, I ^a   Islam, T ^a   Chanan Khan, A ^a   Hahn, T ^a   Wentling, D ^a   Becker, J L ^a   McCarthy, P L ^a   Alam, A R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Multiple myeloma; Peripheral blood stem cell transplantation; Thalidomide

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CASE REPORT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; STEM CELL MOBILIZATION; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 85047695783     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703522     Document Type: Article

References (19)

1. Effective treatment of advanced multiple myeloma refractory to alkylating agents
2. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma
3. High dose cytosine arabinoside in multiple myeloma
4. Vincristine and oral etoposide in refractory multiple myeloma
5. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma
6. Hyper CVAD for VAD-resistant multiple myeloma
7. Antitumor activity of thalidomide in refractory multiple myeloma
8. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
9. Thalidomide in the treatment of relapsed multiple myeloma
10. Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug
11. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival
12. Thalidomide on the comeback trail
13. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
14. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation
15. Successful treatment of multiple myeloma relapsing after high dose therapy and autologous transplantation with thalidomide as a single agent
16. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
17. Thalidomide alone or with dexamethasone for multiple myeloma
18. Single course DTPACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma
19. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma